BR112017008280A2 - método para o tratamento de um paciente - Google Patents

método para o tratamento de um paciente

Info

Publication number
BR112017008280A2
BR112017008280A2 BR112017008280-2A BR112017008280A BR112017008280A2 BR 112017008280 A2 BR112017008280 A2 BR 112017008280A2 BR 112017008280 A BR112017008280 A BR 112017008280A BR 112017008280 A2 BR112017008280 A2 BR 112017008280A2
Authority
BR
Brazil
Prior art keywords
patient
treating
cell carcinoma
hpv
cancer
Prior art date
Application number
BR112017008280-2A
Other languages
English (en)
Inventor
Ioannides Tim
Original Assignee
Hpvvax, Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax, Llc. filed Critical Hpvvax, Llc.
Publication of BR112017008280A2 publication Critical patent/BR112017008280A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

um método para tratar ou reduzir a incidência de recorrência de câncer, tumores benignos ou lesões associadas a hpv, incluindo câncer da pele, e particularmente carcinoma de células escamosas (cce) e carcinoma basocelular (cbc), administrando uma ou mais doses de hpv recombinante a um paciente
BR112017008280-2A 2014-10-24 2015-10-23 método para o tratamento de um paciente BR112017008280A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068332P 2014-10-24 2014-10-24
US62/068,332 2014-10-24
PCT/US2015/057150 WO2016065281A1 (en) 2014-10-24 2015-10-23 Cancer and skin lesion treatment

Publications (1)

Publication Number Publication Date
BR112017008280A2 true BR112017008280A2 (pt) 2018-01-02

Family

ID=55761638

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008280-2A BR112017008280A2 (pt) 2014-10-24 2015-10-23 método para o tratamento de um paciente

Country Status (15)

Country Link
US (1) US10238729B2 (pt)
EP (1) EP3209676A4 (pt)
JP (1) JP6663438B2 (pt)
KR (1) KR102285401B1 (pt)
CN (1) CN107001430A (pt)
AU (1) AU2015335652B2 (pt)
BR (1) BR112017008280A2 (pt)
CA (1) CA2965498A1 (pt)
CL (1) CL2017001008A1 (pt)
IL (1) IL251825B2 (pt)
MX (1) MX2017005418A (pt)
MY (1) MY195018A (pt)
PH (1) PH12017500754A1 (pt)
SG (1) SG11201703262UA (pt)
WO (1) WO2016065281A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018010338A (es) * 2016-02-27 2018-11-09 Hpvvax Llc Metodo y composicion para tratamiento del cancer o una lesion de la piel utilizando una vacuna.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354662T1 (de) * 2001-03-23 2007-03-15 Deutsches Krebsforsch Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
ATE503492T1 (de) 2002-12-20 2011-04-15 Glaxosmithkline Biolog Sa Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
JP2008502633A (ja) * 2004-06-16 2008-01-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
US8399610B2 (en) 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
US7709010B2 (en) * 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
CN101530614A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 五价重组人乳头瘤病毒疫苗
CN101530612A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 16型重组人乳头瘤病毒疫苗
WO2009127988A1 (en) 2008-04-16 2009-10-22 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
CN107080833A (zh) * 2009-04-10 2017-08-22 约翰·霍普金斯大学 作为广谱人类乳头状瘤病毒（hpv）疫苗的乳头状瘤病毒样颗粒（vlp）
ES2845212T3 (es) * 2009-04-13 2021-07-26 Inst Nat Sante Rech Med Partículas de HPV y usos de las mismas
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
EP2444103B1 (en) 2009-06-19 2017-12-20 Eyegene Inc. Vaccine for cervical cancer
JP2012530505A (ja) * 2009-06-25 2012-12-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規ヒトパピローマウイルス（ｈｐｖ）タンパク質構築物及びｈｐｖ疾患の予防におけるそれらの使用
AR074485A1 (es) 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
CA2838387A1 (en) * 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
CN104203270A (zh) * 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
US20150086587A1 (en) * 2012-03-28 2015-03-26 Kansas State University Research Foundation Vaccine adjuvant
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2015054678A2 (en) 2013-10-13 2015-04-16 The Board Of Trustees Of The University Of Arkanasas Human papilloma virus therapeutic vaccine

Also Published As

Publication number Publication date
EP3209676A1 (en) 2017-08-30
CN107001430A (zh) 2017-08-01
AU2015335652B2 (en) 2020-07-02
MY195018A (en) 2023-01-03
AU2015335652A1 (en) 2017-05-25
CL2017001008A1 (es) 2017-11-24
KR20170072279A (ko) 2017-06-26
WO2016065281A1 (en) 2016-04-28
MX2017005418A (es) 2017-11-30
CA2965498A1 (en) 2016-04-28
PH12017500754A1 (en) 2017-10-30
IL251825A0 (en) 2017-06-29
SG11201703262UA (en) 2017-05-30
IL251825B1 (en) 2023-05-01
US20160114023A1 (en) 2016-04-28
US10238729B2 (en) 2019-03-26
JP6663438B2 (ja) 2020-03-11
IL251825B2 (en) 2023-09-01
JP2017531699A (ja) 2017-10-26
KR102285401B1 (ko) 2021-08-02
EP3209676A4 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
NZ749218A (en) Androgen receptor modulator and uses thereof
NZ746338A (en) Use of alphavirus and zap inhibitor in the preparation of an antitumor drug, and antitumor drugs comprising the same
MX2021006734A (es) Metodo para tratar el cancer.
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
MX2019008063A (es) 17a, 21-diesteres de cortexolona para uso en el tratamiento de tumores.
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
IN2014MU00303A (pt)
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
AU2016206832A8 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
BR112017021700A2 (pt) composições terapêuticas e métodos de uso para o tratamento do câncer
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MY181685A (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer
EP3597207A4 (en) COMPOSITION TYPE OF TRADITIONAL CHINESE MEDICINE FOR TREATMENT OF TUMORS, METHOD OF MANUFACTURING THEREOF AND USES THEREOF
WO2019103449A3 (ko) 항암바이러스의 간동맥 투여를 이용한 간암 치료방법
MX370519B (es) Sulfonamidas con sustitucion biarilo y su uso.
CL2018002438A1 (es) Método y composición para el tratamiento del cáncer o una lesión de la piel utilizando una vacuna.
BR112015025697A2 (pt) cepa do vírus vaccinia mutante, uso da cepa do vírus vaccinia mutante, método para a produção de um produto de gene recombinante e produto de gene recombinante
BR112017008280A2 (pt) método para o tratamento de um paciente
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]